The earnings call highlighted strong growth in QUVIVIQ's sales and improvements in operating results, along with positive developments in strategic partnerships and financial stability. However, challenges persist with flat U.S. sales, reliance on regulatory processes, and liquidity constraints.

Company Guidance -

Q3 2025

In the call, Idorsia provided detailed guidance for its fiscal performance, emphasizing several key metrics. The company's net sales for the first half of 2025 experienced significant growth, with QUVIVIQ sales more than doubling from CHF 23 million to CHF 56 million, driven by strong demand in Europe and Canada. The non-GAAP operating result improved markedly, reducing losses from CHF 170 million to CHF 15 million. The company also achieved a U.S. GAAP net income of CHF 52 million, supported by a strategic cost-saving initiative that cut operational costs by nearly CHF 50 million compared to the previous year. Additionally, Idorsia extended its cash runway to the end of 2026 and maintained an unchanged guidance for its Idorsia-led business, projecting sales of CHF 130 million and a non-GAAP EBIT loss of CHF 175 million. The company aims to reach commercial profitability in 2026 and overall profitability by the end of 2027.

Strong Commercial Performance of QUVIVIQ

QUVIVIQ net sales in the first half of 2025 more than doubled compared to last year, rising from CHF 23 million to CHF 56 million, driven by Europe and Canada.

Improvement in Non-GAAP Operating Results

Non-GAAP operating results improved significantly from a loss of CHF 170 million in the first half of 2024 to a loss of CHF 15 million in the first half of 2025.

Expansion of Global Footprint

QUVIVIQ's global footprint is expanding with availability in North America, Europe, Japan, and soon China. Public reimbursement has been secured in key European markets.

Financial Stability and Cash Runway Extension

Idorsia secured additional financial stability with the extension of their cash runway to the end of 2026 through a CHF 150 million funding facility.

Positive Feedback for TRYVIO

TRYVIO's FDA approval with the removal of REMS requirement, making it easier to prescribe and distribute, alongside its efficacy and safety profile in patients with comorbid conditions.

Idorsia Ltd (CH:IDIA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:IDIA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.18 / -	-0.462	―	―	―
Jul 30, 2025	2025 (Q2)	-0.20 / -0.20	-0.54	62.96% (+0.34)	―	―
Apr 30, 2025	2025 (Q1)	- / -0.61	0.13	-569.23% (-0.74)	―	―
Mar 04, 2025	2024 (Q4)	-0.56 / -0.39	-0.675	42.22% (+0.29)	―	―
Oct 29, 2024	2024 (Q3)	-0.53 / -0.46	0.96	-148.13% (-1.42)	―	―
Jul 25, 2024	2024 (Q2)	-0.36 / -0.54	-1.08	50.00% (+0.54)	―	―
May 21, 2024	2024 (Q1)	0.17 / 0.13	-1.19	110.92% (+1.32)	―	―
Apr 25, 2024	2023 (Q4)	- / -	-1.19	―	―	―
Oct 24, 2023	2023 (Q3)	-0.97 / 0.96	-1.14	184.21% (+2.10)	―	―
Jul 25, 2023	2023 (Q2)	-0.95 / -1.08	-1.25	13.60% (+0.17)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:IDIA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	CHF2.71	CHF3.34	+23.25%
Apr 30, 2025	CHF1.18	CHF1.29	+9.32%
Mar 04, 2025	CHF1.24	CHF1.18	-4.84%
Oct 29, 2024	CHF1.18	CHF1.18	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Idorsia Ltd (CH:IDIA) report earnings?

Idorsia Ltd (CH:IDIA) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Idorsia Ltd (CH:IDIA) earnings time?

Idorsia Ltd (CH:IDIA) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Idorsia Ltd stock?

The P/E ratio of Idorsia Ltd is N/A.

What is CH:IDIA EPS forecast?

CH:IDIA EPS forecast for the fiscal quarter 2025 (Q3) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing